South Dakota Investment Council Sells 32,570 Shares of Bristol Myers Squibb Company $BMY

South Dakota Investment Council trimmed its position in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 20.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 127,338 shares of the biopharmaceutical company’s stock after selling 32,570 shares during the quarter. South Dakota Investment Council’s holdings in Bristol Myers Squibb were worth $7,946,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Garrison Point Advisors LLC increased its position in shares of Bristol Myers Squibb by 1.7% in the third quarter. Garrison Point Advisors LLC now owns 15,461 shares of the biopharmaceutical company’s stock valued at $965,000 after buying an additional 263 shares in the last quarter. Cibc World Market Inc. raised its position in shares of Bristol Myers Squibb by 55.2% in the third quarter. Cibc World Market Inc. now owns 635,279 shares of the biopharmaceutical company’s stock valued at $39,641,000 after buying an additional 225,851 shares during the last quarter. Edgestream Partners L.P. acquired a new position in Bristol Myers Squibb in the 3rd quarter valued at $12,072,000. Paralel Advisors LLC lifted its position in Bristol Myers Squibb by 1.1% during the third quarter. Paralel Advisors LLC now owns 38,523 shares of the biopharmaceutical company’s stock worth $2,404,000 after buying an additional 432 shares during the period. Finally, Hall Capital Management Co. Inc. lifted its holdings in shares of Bristol Myers Squibb by 2.4% during the 3rd quarter. Hall Capital Management Co. Inc. now owns 26,196 shares of the biopharmaceutical company’s stock worth $1,635,000 after acquiring an additional 623 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Julia A. Haller sold 3,800 shares of the firm’s stock in a transaction on Thursday, November 5th. The stock was sold at an average price of $63.31, for a total transaction of $240,578.00. Following the transaction, the director directly owned 30,279 shares of the company’s stock, valued at approximately $1,916,963.49. This trade represents a 11.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders own 0.05% of the company’s stock.

Analyst Ratings Changes

BMY has been the topic of several research reports. JPMorgan Chase & Co. increased their target price on Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Weiss Ratings restated a “buy (b-)” rating on shares of Bristol Myers Squibb in a research note on Monday. Citigroup reissued a “neutral” rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. Truist Financial set a $70.00 price objective on shares of Bristol Myers Squibb in a report on Friday, October 30th. Finally, Argus upgraded Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target for the company in a report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Bristol Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $65.46.

View Our Latest Analysis on BMY

Latest Bristol Myers Squibb News

Here’s some of the latest news about BMY:

  • Positive Sentiment: The company also highlighted continued momentum in its growth portfolio: revenue rose 12% year over year to $7.7 billion, and eight medicines each had annualized sales above $1 billion. This may help reassure investors about growth as older products face patent expirations. The Motley Fool article
  • Negative Sentiment: Shares broke below their 200-day moving average, a technical signal that can encourage selling and add pressure in the near term. American Banking News article
  • Negative Sentiment: A Zacks comparison identified Merck as the stronger investment, citing its stock performance, oncology position, pipeline expansion and growth drivers. That relative assessment may weigh on sentiment toward BMY, though it is an analyst opinion rather than a company-specific development. Zacks article

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY opened at $59.49 on Thursday. The firm’s 50 day moving average is $61.65 and its two-hundred day moving average is $60.41. The firm has a market capitalization of $121.61 billion, a P/E ratio of 13.19, a PEG ratio of 0.32 and a beta of 0.20. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79. Bristol Myers Squibb Company has a 52 week low of $45.26 and a 52 week high of $68.64.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The business had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. During the same period in the previous year, the firm posted $1.63 earnings per share. The business’s revenue was up 6.9% on a year-over-year basis. Analysts anticipate that Bristol Myers Squibb Company will post 6.46 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd were paid a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.2%. Bristol Myers Squibb’s payout ratio is presently 55.88%.

About Bristol Myers Squibb

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Further Reading

Institutional Ownership by Quarter for Bristol Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.